Prosus announced a €400 million (US$460 million) investment into Alan, a European health and insurance technology company, valuing the firm at €5.5 billion (US$6.3 billion). The investment round, totaling €480 million with participation from existing investors Teachers' Venture Growth and Index Ventures plus new investor Dara Holdings, consists of both primary and secondary equity. Prosus identified AI-driven healthcare transformation as a significant global opportunity, with Alan's integrated platform combining insurance, care delivery, and prevention positioning the company to define the future of health technology.
Prosus Commits €400M in Primary and Secondary Equity
Prosus leads the €480 million funding round with a €400 million (US$460 million) investment into Alan. The investment consists of both primary and secondary equity. Existing investors Teachers' Venture Growth (TVG) and Index Ventures participate in the round alongside new investor Dara Holdings. The transaction values Alan at €5.5 billion (US$6.3 billion).
Alan Reports €800M Annual Recurring Revenue in Q1 2026
Alan reached more than €800 million in Annual Recurring Revenue as of Q1 2026, representing 53% year-on-year growth. The company serves more than 1.1 million individuals and achieved profitability in France, its largest market. Alan scales with limited headcount growth, demonstrating operating leverage of its AI-led model. The company built an AI-native healthcare platform that integrates insurance, care, and prevention in a single personalized experience.
Prosus and Alan Plan Mutual Ecosystem Benefits
Prosus will support Alan's consumer offering scaling, drive Alan's expansion in large international markets with strong Prosus presence, and accelerate Alan's AI-led product development including via access to Prosus' Large Commerce Model (LCM). Alan will help Prosus expand its consumer ecosystem proposition into healthcare and bolster Prosus' life assistant strategy.
Executives Outline Healthcare Platform Vision
Fahd Beg, Head of Investments at Prosus Group, stated: "Healthcare presents one of the most significant global opportunities for AI-led transformation. Alan has built something unique: an integrated platform where insurance, prevention and care delivery reinforce each other, creating an exceptional healthcare experience for consumers and outstanding platform engagement. We're excited to partner with Alan to accelerate its international expansion and unlock value through our ecosystem."
Jean-Charles Samuelian-Werve, Co-founder and CEO of Alan, said: "Health can't wait, not for symptoms to get worse, not for a six-month appointment, not for the system to catch up. Yet that is exactly how healthcare works today. We believe great health is a universal right, and that prevention should be too. For ten years we have shown that technology can turn healthcare from reactive to proactive, helping people act early instead of reacting late. That is what prevention insurance is, and it's the category we are building. We selected Prosus for their very deep expertise in international expansion and consumer products and to benefit from the incredible ecosystem they are building. We are still at the very beginning of what Alan can become."
Investment Awaits French Regulatory Approval
The closing of this financing round is subject to applicable regulatory approvals, including from the relevant French financial authorities.
FAQ
What is the valuation of Alan following Prosus' investment?
Alan is valued at €5.5 billion (US$6.3 billion) following the €480 million funding round led by Prosus with a €400 million investment.
What was Alan's Annual Recurring Revenue in Q1 2026?
Alan reached more than €800 million in Annual Recurring Revenue as of Q1 2026, up 53% year-on-year, and achieved profitability in France, its largest market.
Who participated in Alan's latest funding round?
Prosus led the round with €400 million, joined by existing investors Teachers' Venture Growth and Index Ventures, and new investor Dara Holdings, for a total round of €480 million.
